Back to search

Article

Association between CYP2D6 genotype and vortioxetine exposure and therapeutic failure - a retrospective, cohort study

2020-11-24

Abstract excerpt

The antidepressant vortioxetine is primarily metabolised by the polymorphic enzyme CYP2D6. The objective of this study was to investigate the effect of CYP2D6 genotype on exposure and therapeutic failure of vortioxetine. The analysis included data from CYP2D6-genotyped patients (N=458) on vortioxetine treatment from a Norwegian therapeutic drug monitoring database. Compared with CYP2D6 normal metabolizers (NMs; N=...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f36f189b-b16e-587f-bcd2-7cb2b03c42ba
DOI
10.22541/au.160622167.72705375/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Association between CYP2D6 genotype and vortioxetine exposure and therapeutic failure - a retrospective, cohort studyDOI 10.22541/au.160622167.72705375/v1
Association Between CYP2D6 Metabolizer Status and Vortioxetine Exposure and Treatment Switching: A Retrospective, Naturalistic Cohort Study Using Therapeutic Drug Monitoring Data From 640 Patients.Semantic proximity
Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.Semantic proximity
Antidepressant Treatment and Altered CYP2D6 ActivitySemantic proximity
An observational study of Venlafaxine and CYP2D6 in clinical practice.Semantic proximity
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.Semantic proximity
Association between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder - a retrospective cohort studySemantic proximity
Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.Semantic proximity
Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data.Semantic proximity
The role of the poor metabolizer genotype CYP2D6 and CYP1A2 phenotype in the pharmacokinetics of duloxetine and venlafaxine-A case report.Semantic proximity
Association between CYP2D6 genotype and treatment effectiveness and safety in 99 hospitalized patients with major depressive disorder a retrospective cohort study CYP2D6 genotype and antidepressant response.Semantic proximity
CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.Semantic proximity
Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.Semantic proximity
Select a neighboring publication to make it the new centre.